MedTrace Logo

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

NCT02730715 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-09-01

No results posted yet for this study

Summary

This study aims to study the effects that two standard of care immunosuppression induction regimens have on regulatory T cells (Treg) in live donor renal transplant recipients. Both regimens are currently used in this hospital for early immunosuppression induction but the effects on Treg numbers and function is not well understood and likely will impact long term immune function.

Conditions

  • KIDNEY TRANSPLANTATION

Interventions

DRUG

Basiliximab

Periodic blood collection to monitor Treg cells

DRUG

Thymoglobulin

Periodic blood collection to monitor Treg cells

Sponsors & Collaborators

Principal Investigators

  • Matthew L Levine, MD · University of Pennsylvania

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730715 on ClinicalTrials.gov